FDA panel promotes misinformation about antidepressants during pregnancy, psychiatrists say
The panel had promised to feature diverse viewpoints about antidepressants and pregnancy. But nearly all of the 10 panelists bucked medical consensus on the drugs' safety and emphasized what they said were risks of taking the drugs while pregnant — such as causing autism, miscarriages or birth defects. In some cases, they claimed that antidepressants don't work at all and that depression goes away on its own.
Three of the 10 panelists were from outside the United States. Another runs a clinic to help people taper off of psychiatric drugs.
'They were really rousing concerns about safety that are not evidence-based or established and not at all balanced with concerns about the risks of untreated depression,' said Dr. Joseph Goldberg, a clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Jennifer Payne, director of the Reproductive Psychiatry Research Program at the University of Virginia, said, 'I'm disappointed that the FDA brought people in from outside of the United States when there's so many experts here in the United States who truly know this [medical] literature inside and out.'
A spokesperson for the FDA said in a statement that the claim that the panel was one-sided was 'insulting to the independent scientists, clinicians, and researchers who dedicate their expertise to these panels.' The spokesperson added that FDA Commissioner Martin Makary 'has an interest in ensuring policies reflect the latest gold standard science and protect public health.'
Health and Human Services Secretary Robert F. Kennedy Jr. has called for a probe into the risks of antidepressants. His 'Make America Healthy Again' report in May claimed there were 'potentially major long-term repercussions' associated with use of the drugs in childhood.
The panel discussion focused on a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, which includes Lexapro, Prozac and Zoloft. The medications increase levels of serotonin, a chemical messenger in the brain that can improve mood.
Psychiatrists often advise women who are taking SSRIs to continue doing so during pregnancy, since the risks of untreated depression tend to outweigh the potential risks of the medication to mother and child. However, the decision is a personal one.
For ethical reasons, there are no randomized-control trials of SSRIs in pregnant women, meaning data on potential risks mostly comes from observational studies and drug registries.
Some babies born to mothers taking SSRIs may develop symptoms such as jitteriness, irritability or difficulty eating or sleeping that resolve quickly — what's known as 'neonatal adaptation syndrome.' The symptoms may be caused by medication in the babies' systems or withdrawal from it.
Certain studies have also found a slightly elevated risk of miscarriage associated with antidepressant use in pregnancy, though others have found no association. However, there's no convincing evidence to suggest that SSRIs are linked to autism or birth defects.
'Well-controlled studies continue to not find an association,' Payne said.
Women with histories of depression are also at an increased risk of symptoms' recurring during pregnancy, and depression can come with its own risks — including thoughts of self-harm or low birth weight.
'The best thing a pregnant individual could do for herself and her baby is to get the treatment that they need,' said Dr. Nancy Byatt, a perinatal psychiatrist at UMass Chan Medical School, who wasn't part of the panel.
In addition to raising concerns about side effects, several panelists questioned the efficacy of antidepressants or suggested that data favoring the use of SSRIs was manipulated by the pharmaceutical industry.
'It's been said that SSRIs help people who are severely depressed. They don't,' said David Healy, an FDA panelist and fellow at the Royal College of Psychiatrists in the United Kingdom.
Goldberg and other psychiatrists said that's simply untrue.
'You can say the moon landing was faked. Conspiracy theories abound in our world. But there is not a doubt about whether SSRIs work,' said Goldberg, a past president of the American Society of Clinical Psychopharmacology who has previously consulted for pharmaceutical companies. He said he was invited to join the FDA panel but declined because the language of the invitation suggested it wouldn't be a fair discussion.
Healy, the panelist, also claimed that some people 'recover spontaneously' from depression.
Another panelist, psychologist Roger McFillin — who hosts a podcast that challenges conventional mental health advice — suggested that depression wasn't an illness but rather a product of 'women just naturally experiencing their emotions more intensely.' He added, without evidence, that many women feel coerced into taking antidepressants.
Psychiatrists who weren't part of the discussion broadly decried those characterizations.
'I have never, ever, ever, ever heard of a third party pushing a prescription in pregnancy,' Goldberg said. However, he said he is aware of some obstetrician-gynecologists who aren't as familiar with SSRIs who have wrongly told pregnant patients to stop taking the medications.
The American College of Obstetricians and Gynecologists said in a statement Monday that SSRIs can be lifesaving for some pregnant people.
'Today's FDA panel on SSRIs and pregnancy was alarmingly unbalanced and did not adequately acknowledge the harms of untreated perinatal mood disorders in pregnancy,' it said. 'On a panel of 10 experts, only one spoke to the importance of SSRIs in pregnancy as a critical tool, among others, in preventing the potentially devastating effects of anxiety and depression when left untreated during pregnancy.'
One panelist, Dr. Kay Roussos-Ross, a psychiatrist and an OB-GYN at the University of Florida College of Medicine, was the most vocal advocate for using SSRIs, often pushing back against others' assessments of the risks. Psychiatrists who weren't on the panel praised her science-backed commentary.
'All of us can find a study that agrees with exactly what we think,' Roussos-Ross told the panel. 'But we need to look at the data very objectively.'
Several psychiatrists who weren't on the panel said they worry that the discussion could lead to regulatory action that makes it harder to access SSRIs. For example, one panelist, Dr. Adam Urato, chief of maternal-fetal medicine at MetroWest Medical Center in Framingham, Massachusetts, called for stronger warnings on SSRI labels.
'I am just very nervous that some of the discourse around the risks of antidepressants could lead to even more barriers for people seeking care,' said Dr. Lindsay Lebin, an assistant professor of psychiatry at the University of Colorado Anschutz Medical Campus, who wasn't part of the FDA discussion.
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Business News
an hour ago
- Time Business News
Where to Buy MK-677 in the USA: Top Trusted Sources
If you're looking for MK677 for sale in the USA, it's important to find a source that's both trusted and safe. MK-677, also known as Ibutamoren, is popular in the research world for its ability to boost growth hormone levels and support muscle development. But not all websites or sellers offer pure products. One well-known and reliable name in the industry is PureRawz, a company known for selling high-quality research compounds. In this guide, we'll explain how to find trustworthy places to buy MK-677 online, what to look for before buying, and why purity matters. MK-677 is a compound that acts like a growth hormone secretagogue. This means it helps the body release more growth hormone. It's not a steroid, but many researchers explore it for its effects on muscle mass, fat loss, and recovery. Some of the reported benefits from research use include: Increase in muscle mass Better recovery after workouts Improved sleep quality Reduced fat over time Higher levels of IGF-1 MK-677 is not approved by the FDA for medical use, but it is legal to buy for research purposes. That's why most vendors sell it with a 'for research only' label. So, if you're purchasing it, make sure you understand that it's not meant for personal or human use unless approved by your healthcare provider or part of a study. Since MK-677 is a research compound, it's not regulated like prescription drugs. This means the quality can vary from one seller to another. If you're not careful, you might end up with: A product that contains no active ingredient A fake or low-quality mix Harmful additives That's why choosing a trusted source is very important. You want the product to be pure, third-party tested, and come from a company with a good reputation. Here are some of the top websites where researchers often buy MK-677: PureRawz is one of the most popular and trusted names when it comes to SARMs and research chemicals. They offer MK677 for sale in different forms like liquid, capsules, and powder. Why choose PureRawz: Third-party lab tested Fast shipping in the USA Transparent about ingredients Good customer support Many researchers in the USA prefer PureRawz because they maintain high standards and have been around for a while. Note: was a trusted source but has paused sales. We recommend checking their official website for updates. Chemyo also offers a wide range of research compounds, including MK-677. They focus on quality and lab testing. Their products often come with a QR code that links to lab test results. Pros: High-quality packaging Strong customer base Verified purity Amino Asylum is a U.S.-based vendor known for research-grade products. While they have a wide range of compounds, make sure to confirm third-party lab testing before buying. Before you place an order, here are a few important things to check: Third-party lab testing: Always look for a certificate of analysis (COA) on the product page. Customer reviews: Check real reviews to see what others say about product quality. Clear labeling: The product should say 'for research use only' and include dosage details. Shipping policy: A good vendor should ship quickly and discreetly. Return or refund policy: A solid return policy shows that the company stands behind their product. MK-677 comes in different forms. The two most common are liquid and capsules. Liquid MK-677 is usually more affordable and easier to measure in smaller doses. But it may taste bitter. is usually more affordable and easier to measure in smaller doses. But it may taste bitter. Capsules are easier to use but might cost a little more. Your choice depends on your research needs and budget. Finding MK677 for sale in the USA doesn't have to be risky if you know where to look. Start with trusted names like PureRawz, Chemyo, or other established sources. Always make sure to check for third-party testing and reviews before buying. Don't go for the cheapest option—quality and purity matter most. Whether you're doing a study on muscle recovery or testing its effects on growth hormone levels, always buy from vendors that offer real, lab-tested products. That way, your research will stay accurate and safe. TIME BUSINESS NEWS


Business Upturn
2 hours ago
- Business Upturn
22nd Century Applauds the American Academy of Family Physicians Comments and Support of the FDA's Proposed Reduced Nicotine Mandate to Reduce Smoking, Transform Public Health, Save Lives and Reduce Health Costs
22nd Century VLN ® products are the only combustible cigarettes authorized by the FDA as a reduced nicotine content product that comply with the FDA proposed rule MOCKSVILLE, N.C., July 29, 2025 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today commented on responses provided to the U.S. Food and Drug Administration to date as part of its open comment period on the proposed new Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products . 'In the United States, smoking causes more than 480,000 deaths and costs over $600 billion annually and reduces life expectancy by 10 years. The US government and our federal courts have issued countless warnings concerning nicotine, the effects of nicotine addiction, and the harms caused by smoking since the early 1950's. Implementation of the proposed FDA standard, which would require that all combusted tobacco products sold in the U.S. contain less than 0.7mg of nicotine per gram of tobacco, would directly combat the public health issues resulting from nicotine and nicotine dependence, as outlined by the American Academy of Family Physicians,' said Larry Firestone, Chief Executive Officer of 22nd Century Group. Comments published from the American Academy of Family Physicians (AAFP), which represents more than 128,300 family physicians and medical students across the country, recommend the FDA finalize the proposed mandate as the new standard, including: Establishing a maximum nicotine yield of 0.7 milligrams per gram of total tobacco in cigarettes and other combusted tobacco products Extending the standard to other forms of nicotine consumption, such as e-cigarettes and vapes, as a means to protect children and support quitting. It's letter states: 'Establishing a maximum nicotine yield is a vital step towards curbing nationwide tobacco dependence.' The full comment submission can be read on the AAFP webpage found here . 'The commercial launch of our low nicotine VLN® products which include partner brand products such as Smoker Friendly VLN® and Pinnacle VLN®, demonstrate the commercial viability for cigarettes which are already compliant with the new standard. If licensed from, or produced by 22nd Century, VLN® products can be quickly produced, marketed and sold under the wide array of brands in the tobacco industry,' said Larry Firestone, Chief Executive Officer of 22nd Century Group. About 22nd Century Group, Inc. 22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption. We created our flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to allow consumers to greatly reduce their nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers in the form that they are used to, the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether. Our proprietary non-GMO reduced nicotine tobacco blends are made possible by comprehensive and patented technologies and tobacco plants that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets. VLN® is a registered trademark of 22nd Century Limited LLC. Learn more at , on X (formerly Twitter) , on LinkedIn , and on YouTube . Learn more about VLN® at Cautionary Note Regarding Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as 'anticipate,' 'believe,' 'consider,' 'continue,' 'could,' 'estimate,' 'expect,' 'explore,' 'foresee,' 'goal,' 'guidance,' 'intend,' 'likely,' 'may,' 'plan,' 'potential,' 'predict,' 'preliminary,' 'probable,' 'project,' 'promising,' 'seek,' 'should,' 'will,' 'would,' and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in 'Risk Factors' in the Company's Annual Report on Form 10-K filed on March 20, 2025 and Quarterly Report on Form 10-Q filed on May 13, 2025. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. Investor Relations & Media ContactMatt KrepsInvestor Relations22nd Century Group [email protected] 214-597-8200


New York Post
3 hours ago
- New York Post
Beware: Synthetic kratom 7-OH powers a new opioid crisis
Vape shops are popping up in every neighborhood in America, but few people — even doctors — know that many of these shops are selling a dangerous new opioid. It's concentrated 7-OH, a synthetic byproduct of the kratom plant that binds strongly to the body's opioid receptors — making it up to 13 times more potent than morphine. This addictive compound is ubiquitous, it's being pushed deceptively to consumers, and its use is quietly growing. Advertisement In previous waves of the opioid crisis — prescription opioids, heroin and fentanyl — the Food and Drug Administration realized too late that a public health crisis was raging, and got caught flat-footed. Let's not make that mistake again. On Tuesday, in collaboration with the Drug Enforcement Administration, the FDA began the process of reviewing whether products with unusually high levels of 7-OH should be classified as controlled substances. Advertisement To be clear, the kratom plant leaf, which contains trace amounts of 7-OH and has been consumed for centuries, is not our focus at the FDA. Rather, we are seeking to remove a dangerous synthetic opioid from retail shelves nationwide. As a part of this effort, the FDA issued seven warning letters earlier this month to prominent firms illegally marketing 7-OH products. Already a number of companies have stopped sales, another is recalling its products, and one company's website disappeared entirely. But a DEA classification and warning letters alone won't solve this problem. We must also educate the public to be vigilant about this threat. Advertisement Americans should know that synthetic, concentrated 7-OH products can be marketed as 7-hydroxymitragynine, 7-OH-mitragynine, 7-OHMG, 7-Hydroxy, 7-HMG or 7 — and all these compounds pose significant health risks. The potency of 7-OH greatly increases the risk of overdose and dependence. A 2025 National Institute on Drug Abuse study found that 7-OH resulted in respiratory depression at a magnitude three times more severe than morphine. Given how 7-OH interacts with the brain, we're hearing more and more stories of severe addiction in young people — and of major withdrawal symptoms, including insomnia, anxiety, body aches and sweats. Advertisement We don't have precise statistics about the use of 7-OH. Because it's unregulated, sales data and adverse-event reporting are close to nonexistent. But instead of waiting for a crisis before we respond, we're reading the signs and acting proactively. Despite the critical differences between natural leaf kratom and synthetic 7-OH, many of these opioid products are marketed as 'kratom extract' or 'enhanced kratom' and sold on the same shelves as kratom. Many 7-OH products do not even state how much of the substance the product contains. And since the vast majority of these products come from uninspected manufacturing facilities in India, users may consume inconsistent doses and unknown contaminants. Perhaps most alarming is that 7-OH products are often disguised as attractive candies, gummies and even ice cream cones that parents might never see as a risk. But let's be clear: No FDA-approved drug, food or supplement product contains 7-OH, and none of the health claims made about these products have been federally substantiated. Advertisement Public safety is a priority for President Trump and his administration. To support the FDA's broader actions on 7-OH, the National Institutes of Health will be initiating studies to better understand the substance's effects. While some 7-OH products claim to provide pain relief, clinicians and people struggling with addiction should not view this synthetic opioid as a safer alternative — and store owners, too, should be aware that 7-OH is not just another harmless product. A special FDA resource page, 'Hiding in Plain Sight,' provides more about the risks of 7-OH and how to avoid them. Historically, the medical establishment has been slow to understand and respond to new products as they come to market. Advertisement From cigarettes to social media, it often takes decades before we recognize pervasive harms. But as with tobacco, we know that public awareness can drive behavior change — and massive public health improvements can follow. Even better than rolling back a public health crisis would be never having one in the first place. Let's not allow 7-OH to drive the next wave of the US opioid epidemic. Dr. Marty Makary is the commissioner of the Food and Drug Administration.